MA44629A - Antagonistes de c5ar solubles - Google Patents

Antagonistes de c5ar solubles

Info

Publication number
MA44629A
MA44629A MA044629A MA44629A MA44629A MA 44629 A MA44629 A MA 44629A MA 044629 A MA044629 A MA 044629A MA 44629 A MA44629 A MA 44629A MA 44629 A MA44629 A MA 44629A
Authority
MA
Morocco
Prior art keywords
c5ar antagonists
soluble
soluble c5ar
antagonists
c5ar
Prior art date
Application number
MA044629A
Other languages
English (en)
Inventor
Pingchen Fan
Antoni Krasinski
Venkat Reddy Mali
Shichang Miao
Sreenivas Punna
Yang Song
Valentino J Stella
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA44629A publication Critical patent/MA44629A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
MA044629A 2016-04-04 2017-04-03 Antagonistes de c5ar solubles MA44629A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662317721P 2016-04-04 2016-04-04

Publications (1)

Publication Number Publication Date
MA44629A true MA44629A (fr) 2021-03-24

Family

ID=59960805

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044629A MA44629A (fr) 2016-04-04 2017-04-03 Antagonistes de c5ar solubles

Country Status (18)

Country Link
US (4) US20170283446A1 (fr)
EP (1) EP3439658B1 (fr)
JP (1) JP7121722B2 (fr)
KR (1) KR102395093B1 (fr)
CN (1) CN109310686B (fr)
AR (1) AR108097A1 (fr)
AU (1) AU2017246228B2 (fr)
CA (1) CA3019137A1 (fr)
CL (1) CL2018002803A1 (fr)
IL (1) IL261997B (fr)
MA (1) MA44629A (fr)
MX (1) MX2018011831A (fr)
NZ (1) NZ747259A (fr)
RU (1) RU2748260C2 (fr)
SG (1) SG11201808625QA (fr)
TW (1) TWI760331B (fr)
WO (1) WO2017176620A2 (fr)
ZA (1) ZA201806632B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3682879B1 (fr) 2014-09-29 2022-08-03 ChemoCentryx, Inc. Procédés et intermédiaires pour la préparation d'antagonistes c5ar
WO2017123716A1 (fr) 2016-01-14 2017-07-20 Chemocentryx, Inc. Procédé de traitement d'une glomérulopathie à c3
RU2748260C2 (ru) 2016-04-04 2021-05-21 Кемосентрикс, Инк. РАСТВОРИМЫЕ С5аR АНТАГОНИСТЫ
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
EP4272821A3 (fr) 2017-04-03 2024-01-03 InflaRx GmbH Traitement de maladies inflammatoires au moyen d'inhibiteurs de l'activité c5a
BR112019025049A2 (pt) * 2017-05-31 2020-06-16 Chemocentryx, Inc. Anéis 6- 5 fundidos como inibidores de c5a
MX2019014292A (es) 2017-05-31 2022-04-07 Chemocentryx Inc Anillos 5-5 fusionados como inhibidores c5a.
KR20200020727A (ko) 2017-06-23 2020-02-26 인플라알엑스 게엠베하 C5a 활성의 억제제를 사용한 염증 질병의 치료
AU2018326785B2 (en) 2017-09-03 2023-03-02 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors
EP3703687A4 (fr) 2017-10-30 2021-04-07 ChemoCentryx, Inc. Composés deutérés utilisés comme immunomodulateurs
JP2021501159A (ja) * 2017-10-31 2021-01-14 ケモセントリックス，インコーポレイティド Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少
EP3716991A4 (fr) * 2017-12-01 2021-09-08 Soricimed Biopharma Inc. Inhibiteurs de trpv6 et polythérapies pour le traitement de cancers
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
KR20200110656A (ko) 2017-12-22 2020-09-24 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 5,5-융합 고리 화합물
MX2020010390A (es) 2018-04-02 2021-01-15 Chemocentryx Inc Profarmacos de antagonistas de c5ar biciclicos fusionados.
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
MA52808A (fr) 2018-06-07 2021-04-14 Chemocentryx Inc Dosage et effet d'un antagoniste de c5a avec une vasculite associée aux anca
WO2020112961A1 (fr) 2018-11-30 2020-06-04 Chemocentryx, Inc. Formulations de capsules
MX2021010283A (es) * 2019-02-26 2021-09-30 Equillium Inc Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
CN111658647A (zh) * 2019-03-08 2020-09-15 首都医科大学宣武医院 沙利度胺及其衍生物的用途
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
KR20220058605A (ko) * 2019-09-04 2022-05-09 세다르스-신나이 메디칼 센터 고형 장기 이식 수여자의 장기 면역억제를 위한 칼시뉴린 억제제 불포함 ctla4-ig + 항-il6/il6r의 용도
EP3868368A1 (fr) * 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Inhibiteur de l'activité de cxcl8 (interleukine-8), combinaison d'un corticostéroïde et composition pharmaceutique et son utilisation
US20230158060A1 (en) 2020-03-27 2023-05-25 Inflarx Gmbh Inhibitors of C5a for the Treatment of Corona Virus Infection
MX2022015872A (es) 2020-06-11 2023-05-16 Provention Bio Inc Metodos y composiciones para prevenir diabetes tipo 1.
WO2022057910A1 (fr) * 2020-09-17 2022-03-24 I-Mab Biopharma Co., Ltd Polythérapies ciblant des voies c5ar et pd-1/pd-l1
US11844790B2 (en) 2020-10-28 2023-12-19 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
JP2024500752A (ja) * 2020-12-21 2024-01-10 ケモセントリックス， インコーポレイテッド Ｃ５ａ阻害剤を用いたｃ３糸球体腎症の治療
IT202100019454A1 (it) * 2021-07-22 2023-01-22 Genetic S P A Process for the preparation of budesonide 21-phosphate

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DE69822514T2 (de) * 1997-12-31 2005-03-24 The University Of Kansas, Lawrence Wasserlösliche pro-pharmaka von arzneistoffen, die ein tertiäres amin enthalten, und verfahren zu ihrer herstellung
DE60039921D1 (de) 2000-09-29 2008-09-25 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor-modulatoren
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
WO2003082828A1 (fr) 2002-03-28 2003-10-09 Neurogen Corporation Tetrahydroisoquinoleines substituees servant de modulateurs du recepteur c5a
CA2479928A1 (fr) 2002-03-28 2003-10-09 Neurogen Corporation Biarylamides substitues en tant que modulateurs du recepteur c5a
WO2003084524A1 (fr) 2002-03-29 2003-10-16 Neurogen Corporation Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires
WO2004018460A1 (fr) 2002-08-21 2004-03-04 Neurogen Corporation Aminomethyl imidazoles en tant que modulateurs de recepteurs c5a
CA2504941C (fr) 2002-11-08 2012-06-26 Neurogen Corporation 6-arylpyridines substituees en position 3
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
CN1964979B (zh) * 2004-04-09 2011-07-27 中外制药株式会社 新颖的水溶性前药
BRPI0708644A2 (pt) 2006-03-07 2011-06-07 Bristol-Myers Squibb Company compostos de pró-fármaco de anilina de pirrolotriazina úteis como inibidores de cinase
CN101139358B (zh) 2006-09-07 2011-10-12 浙江大德药业集团有限公司 乙氧基康普立停及其前药的制备和用途
SG176464A1 (en) * 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
US8106209B2 (en) * 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
CA2965223C (fr) * 2008-12-22 2019-09-24 Chemocentryx, Inc. Antagonistes de c5ar
JP2013529647A (ja) * 2010-06-24 2013-07-22 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
WO2013032964A1 (fr) * 2011-08-26 2013-03-07 Board Of Regents Of The University Of Nebraska Compositions et méthodes pour la prévention et le traitement de biofilms
AR092529A1 (es) * 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN105377848A (zh) * 2013-06-11 2016-03-02 拜耳制药股份公司 取代的三唑并吡啶的前体药物衍生物
RU2748260C2 (ru) 2016-04-04 2021-05-21 Кемосентрикс, Инк. РАСТВОРИМЫЕ С5аR АНТАГОНИСТЫ

Also Published As

Publication number Publication date
CN109310686B (zh) 2022-06-21
IL261997A (en) 2018-10-31
RU2018138550A3 (fr) 2020-05-29
CA3019137A1 (fr) 2017-10-12
EP3439658A2 (fr) 2019-02-13
WO2017176620A2 (fr) 2017-10-12
EP3439658B1 (fr) 2021-11-24
US10329314B2 (en) 2019-06-25
US20190270761A1 (en) 2019-09-05
ZA201806632B (en) 2022-04-28
AR108097A1 (es) 2018-07-18
CN109310686A (zh) 2019-02-05
RU2018138550A (ru) 2020-05-19
US20190010177A1 (en) 2019-01-10
KR102395093B1 (ko) 2022-05-04
NZ747259A (en) 2022-11-25
US20170283446A1 (en) 2017-10-05
IL261997B (en) 2022-05-01
SG11201808625QA (en) 2018-10-30
MX2018011831A (es) 2019-02-13
TW201803850A (zh) 2018-02-01
EP3439658A4 (fr) 2019-11-27
AU2017246228A1 (en) 2018-11-01
US10487098B2 (en) 2019-11-26
US11254695B2 (en) 2022-02-22
TWI760331B (zh) 2022-04-11
JP7121722B2 (ja) 2022-08-18
AU2017246228B2 (en) 2021-04-15
US20200262853A1 (en) 2020-08-20
KR20190019047A (ko) 2019-02-26
JP2019515947A (ja) 2019-06-13
RU2748260C2 (ru) 2021-05-21
WO2017176620A3 (fr) 2018-05-11
CL2018002803A1 (es) 2019-04-12
BR112018070214A2 (pt) 2019-01-29

Similar Documents

Publication Publication Date Title
MA44629A (fr) Antagonistes de c5ar solubles
DK3437500T3 (da) Beklædningsgenstand
DK3515887T3 (da) TRPV4-antagonister
DK3143037T3 (da) Alpha4beta7-integrin-thioether-peptidantagonister
DK3713928T3 (da) Hidtil ukendte bradykinin-b2-receptorantagonister
DK3340968T3 (da) Implanterbare naltrexon-tabletter
BR112017012366A2 (pt) desalojamento e liberação de hsc usando antagonista de alfa-9-integrina e antagonista de cxcr4.
DK3604650T3 (da) Beklædningsgenstand
DK3290073T3 (da) Forbindelsesanordning
UA37810S (uk) Совок для сміття
IT201700072559A1 (it) Interfaccia aptica
ES2982217T3 (es) Antagonistas de DP
ES2981980T3 (es) Dispositivo implantable de crecimiento autónomo
DK3310756T3 (da) Thromboxanreceptorantagonister
IT201700024029A1 (it) Dispositivo di bloccaggio
ES1161635Y (es) Buzón inteligente
DK3612146T3 (da) Beklædningsgenstand
IT201700079561A1 (it) Dispositivo di telesoccorso
IT201700064228A1 (it) Riduttore
ES1102633Y (es) Pantalon laboral
MA54534A (fr) Antagonistes
ZA201807767B (en) Angiotensin-1-receptor antagonists
TH178767B (th) ถ้วย
UA37267S (uk) Домофон
ES1189959Y (es) Prenda multifuncional